Invesco’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-167,030
| Closed | -$5.66M | – | 3809 |
|
|
2025
Q4 | $5.66M | Buy |
167,030
+26,486
| +19% | +$823K | ﹤0.01% | 2191 |
|
|
2025
Q3 | $3.62M | Buy |
+140,544
| New | +$1.84M | ﹤0.01% | 2375 |
|
|
2025
Q2 | – | Sell |
-7,363
| Closed | -$71.9K | – | 3849 |
|
|
2025
Q1 | $71.9K | Buy |
7,363
+5,924
| +412% | +$58.3K | ﹤0.01% | 3667 |
|
|
2024
Q4 | $18.2K | Sell |
1,439
-16
| -1% | -$203 | ﹤0.01% | 3743 |
|
|
2024
Q3 | $23.4K | Sell |
1,455
-61
| -4% | -$1.23K | ﹤0.01% | 3736 |
|
|
2024
Q2 | $37K | Sell |
1,516
-175
| -10% | -$8.08K | ﹤0.01% | 3846 |
|
|
2024
Q1 | $121K | Sell |
1,691
-6,454
| -79% | -$897K | ﹤0.01% | 3723 |
|
|
2023
Q4 | $1.62M | Buy |
8,145
+4,988
| +158% | +$617K | ﹤0.01% | 2695 |
|
|
2023
Q3 | $420K | Buy |
3,157
+1,415
| +81% | +$231K | ﹤0.01% | 3288 |
|
|
2023
Q2 | $261K | Sell |
1,742
-149
| -8% | -$23.2K | ﹤0.01% | 3541 |
|
|
2023
Q1 | $278K | Buy |
+1,891
| New | +$382K | ﹤0.01% | 3524 |
|
|
2022
Q4 | – | Sell |
-19,367
| Closed | -$3.73M | – | 4056 |
|
|
2022
Q3 | $3.73M | Buy |
+19,367
| New | +$3.66M | ﹤0.01% | 2365 |
|
|
2022
Q2 | – | Sell |
-1,190
| Closed | -$209K | – | 4124 |
|
|
2022
Q1 | $209K | Buy |
1,190
+6
| +0.5% | +$1.13K | ﹤0.01% | 3762 |
|
|
2021
Q4 | $348K | Sell |
1,184
-6,104
| -84% | -$1.63M | ﹤0.01% | 3547 |
|
|
2021
Q3 | $1.81M | Buy |
7,288
+6,315
| +649% | +$1.67M | ﹤0.01% | 2854 |
|
|
2021
Q2 | $247K | Buy |
+973
| New | +$182K | ﹤0.01% | 3713 |
|
Invesco's RAPT Position: Q1 2026 in Review
Invesco sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 167,030 shares — an estimated $5.66M sold.
Invesco first reported a position in RAPT in Q2 2021 and held it in 16 quarters. The position peaked at $5.66M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Invesco reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Invesco sold 167,030 RAPT Therapeutics shares in Q1 2026, an estimated $5.66M.
- Invesco first reported a position in RAPT Therapeutics in Q2 2021 and held it in 16 quarters.
- Invesco's RAPT Therapeutics position peaked at $5.66M in Q4 2025.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.